V600E is the most commonly encountered BRAF mutation. Braftovi – which Pfizer acquired through its $11.4 billion takeover of Array Biopharma in 2019 – was previously approved in combination ...

BRAF V600E mutations are common in different tumor types (more frequently in melanomas, colon and thyroid carcinomas). BRAF Alterations in Brain Tumors: Different Diagnostic Relevance of BRAF ...

Francis P. Worden, MD, discusses his key takeaways for other oncologists treating patients with radioidine-refractory differentiated thyroid cancer.

There’s been an exciting new development for some patients with metastatic colorectal cancer: a groundbreaking FDA approval has introduced a new treatment option specifically designed for those ...

The cost-effectiveness agency has backed the combination of Braftovi (encorafenib) and Eli Lilly's Erbitux (cetuximab) as a second-line treatment option for BRAF V600E mutated mCRC after an ...

Caris Life Sciences has collected $168 million in new funding to support the growth of its precision medicine platforms, ...

Biomarkers, precision medicine, early detection to revolutionize CRC care in India: Dr. Sumant Gupta: Shardul Nautiyal, ...

In combination with trametinib for the treatment of pediatric patients with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. Not for treatment of colorectal cancer ...